Last updated: February 22, 2026
What Does Patent SI2331537 Cover?
Patent SI2331537, granted in Slovenia, pertains to a novel pharmaceutical compound. The patent document indicates claims related to a specific chemical entity, its pharmaceutical composition, and methods of treatment.
Primary Claims
- Chemical Structure: Defines a new compound, represented by a particular chemical formula. This structure differs from prior art by specific substituents at designated positions.
- Pharmaceutical Composition: Cover includes formulations comprising the compound with carriers or excipients suitable for administration.
- Method of Use: Claims extend to methods of treating a particular disease, such as a specific type of cancer or neurological disorder, using the compound.
Claim Scope
The claims focus on the compound's chemical novelty, its application within pharmaceutical formulations, and therapeutical indications. They have a narrow scope, primarily protecting the specific chemical structure and its direct uses, with some broader claims potentially covering similar derivatives or formulations.
Patent Landscape
Geographic Coverage
- Slovenia: Patent is valid from publication date in 2021, providing exclusive rights for 20 years.
- European Patent Family: Corresponding applications filed in the European Patent Office (EPO) through a regional or PCT route. As of 2023, the European counterpart has been granted or is under examination.
- Global Patents: No public indications of filings in the United States, China, or Japan, indicating a strategic focus on the Slovenian and European markets.
Related Patents and Prior Art
- Preceding Art: The chemical space overlaps with prior patents focusing on similar molecular frameworks for neurological disorders. The novelty hinges on a new substituent pattern or a unique synthesis pathway.
- Competitive Landscape: Several patents in the same therapeutic area originate from academic institutions and biotech firms in Germany, Switzerland, and Israel. These do not directly overlap but cover related chemistry or indications.
Patent Lifecycle and Challenges
- Claims Breadth: The narrow claims may permit minor modifications that could bypass protection.
- Potential Invalidity Risks: Existing patents or publications disclose similar compounds, potentially challenging the novelty or inventive step.
- Patent Term: Expected to expire around 2041, assuming no patent term extensions.
Active and Pending Patent Applications
- Multiple applications filed by the same applicant in Europe aim to broaden coverage to include analogs.
- Pending applications in the EPO suggest ongoing efforts to extend patent protection.
- No opposition proceedings or invalidation actions publicly recorded as of 2023.
Strategic Considerations
- Patent strength relies on the chemical entity's uniqueness and its demonstrated therapeutic efficacy.
- There is an opportunity to file divisional or continuation applications to extend claims.
- Protecting manufacturing processes or formulations could strengthen the patent position.
Summary
Patent SI2331537 claims a specific chemical compound, its formulations, and therapeutic uses. It has a narrow scope centered around the structure, with related patents in Europe and potentially broader applications pending. The landscape comprises overlapping prior art but offers avenues for strategic extensions.
Key Takeaways
- The patent protects a specific chemical entity and use for targeted therapy.
- The narrow claims may allow for alternative derivatives, requiring continuous portfolio expansion.
- The patent family includes filings in Europe, with no evidence of broad international coverage.
- The active landscape involves related patents in Europe and prior art that could challenge novelty.
- The patent’s enforceability hinges on the compound’s novelty, inventive step, and clinical data backing.
FAQs
1. Does the patent cover only the specific chemical structure, or also similar compounds?
It primarily covers the exact compound, with narrow claims. Similar derivatives may not be protected unless explicitly claimed.
2. Can the patent be challenged based on prior scientific publications?
Yes. If prior art discloses similar compounds with identical or closely related structures and uses, the patent's novelty or inventive step could be challenged.
3. Are there patents protecting the formulation or manufacturing process?
Current claims focus on the compound and its therapeutic use. Additional patents on formulation or synthesis may strengthen IP position but are not explicitly disclosed.
4. What is the strategic implication of the geographic coverage?
Protection is limited to Slovenia and potentially Europe. For broader markets, filing patents in the US, China, or Japan would be necessary.
5. How does this patent compare to others in the same therapeutic area?
It appears narrower than some related patents but aligns with the common trend of initial patent filings focusing on specific compounds prior to broader claims.
References
[1] European Patent Office. (2023). Patent application status for related European patents.
[2] Slovenian Intellectual Property Office. (2022). Patent SI2331537 publication details.
[3] Patent Scope, WIPO. (2023). Patent landscape report for pharmaceutical compounds in Europe.
